patients meeting any of the following criteria were excluded from the study. 1. patient had current severe condition meeting one of the following: 1. previous or current hospitalization or requirement of hospitalization for treatment of serious sars-cov-2 related conditions. 2. respiratory distress with respiratory rate ≥30 breaths/min. 3. required supplemental oxygen 4. experienced shock 5. complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion. 2. patient had received or had a plan to receive any of the following prohibited medications or treatments: 1. drugs with actual or possible antiviral drugs and/or possible anti-sars-cov-2 activity including but not limited to remdesivir, chloroquine, hydroxychloroquine, dexamethasone (or alternative corticosteroids to dexamethasone), interferon beta-1b, ribavirin, and other immunomodulatory agents and human immunodeficiency virus protease inhibitors (lopinavir-ritonavir, etc.) for therapeutic purpose of sars-cov-2 infection prior to study drug administration 2. any sars-cov-2 human iv immunoglobulin, convalescent plasma for the treatment of sars-cov-2 infection prior to study drug administration 3. any other investigational device or medical product including but not limited to any monoclonal antibody (tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of sars-cov-2 infection prior to the study drug administration 4. use of medications that are contraindicated with soc 5. sars-cov-2 vaccine prior to the study drug administration

patients meeting any of the following criteria were excluded from the study. 1. patient had current severe condition meeting one of the following: 1. previous or current hospitalization or requirement of hospitalization for treatment of serious sars-cov-2 related conditions. 2. respiratory distress with respiratory rate ≥30 breaths/min. 3. required supplemental oxygen 4. experienced shock 5. complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion. 2. patient had received or had a plan to receive any of the following prohibited medications or treatments: 1. drugs with actual or possible antiviral drugs and/or possible anti-sars-cov-2 activity including but not limited to remdesivir, chloroquine, hydroxychloroquine, dexamethasone (or alternative corticosteroids to dexamethasone), interferon beta-1b, ribavirin, and other immunomodulatory agents and human immunodeficiency virus protease inhibitors (lopinavir-ritonavir, etc.) for therapeutic purpose of sars-cov-2 infection prior to study drug administration 2. any sars-cov-2 human iv immunoglobulin, convalescent plasma for the treatment of sars-cov-2 infection prior to study drug administration 3. any other investigational device or medical product including but not limited to any monoclonal antibody (tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of sars-cov-2 infection prior to the study drug administration 4. use of medications that are contraindicated with soc 5. sars-cov-2 vaccine prior to the study drug administration

patients meeting any of the following criteria were excluded from the study. patient had current severe condition meeting one of the following: previous or current hospitalization or requirement of hospitalization for treatment of serious sars-cov-2 related conditions. respiratory distress with respiratory rate ≥30 breaths/min. required supplemental oxygen experienced shock complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion. patient had received or had a plan to receive any of the following prohibited medications or treatments: drugs with actual or possible antiviral drugs and/or possible anti-sars-cov-2 activity including but not limited to remdesivir, chloroquine, hydroxychloroquine, dexamethasone (or alternative corticosteroids to dexamethasone), interferon beta-1b, ribavirin, and other immunomodulatory agents and human immunodeficiency virus protease inhibitors (lopinavir-ritonavir, etc.) for therapeutic purpose of sars-cov-2 infection prior to study drug administration any sars-cov-2 human iv immunoglobulin, convalescent plasma for the treatment of sars-cov-2 infection prior to study drug administration any other investigational device or medical product including but not limited to any monoclonal antibody (tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of sars-cov-2 infection prior to the study drug administration use of medications that are contraindicated with soc sars-cov-2 vaccine prior to the study drug administration

patients meeting any of the following criteria were excluded from the study. patient had current severe condition meeting one of the following: previous or current hospitalization or requirement of hospitalization for treatment of serious sars-cov-2 related conditions. respiratory distress with respiratory rate ≥30 breaths/min. required supplemental oxygen experienced shock complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion. patient had received or had a plan to receive any of the following prohibited medications or treatments: drugs with actual or possible antiviral drugs and/or possible anti-sars-cov-2 activity including but not limited to remdesivir, chloroquine, hydroxychloroquine, dexamethasone (or alternative corticosteroids to dexamethasone), interferon beta-1b, ribavirin, and other immunomodulatory agents and human immunodeficiency virus protease inhibitors (lopinavir-ritonavir, etc.) for therapeutic purpose of sars-cov-2 infection prior to study drug administration any sars-cov-2 human iv immunoglobulin, convalescent plasma for the treatment of sars-cov-2 infection prior to study drug administration any other investigational device or medical product including but not limited to any monoclonal antibody (tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of sars-cov-2 infection prior to the study drug administration use of medications that are contraindicated with soc sars-cov-2 vaccine prior to the study drug administration

patient with severe condition meeting one of the following: previously or currently hospitalized or requires hospitalization for treatment of serious sars-cov-2 related conditions. respiratory distress with respiratory rate ≥30 breaths/min. requires supplemental oxygen experience shock complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion. patient who has received or has a plan to receive any of following prohibited medications or treatments: drugs with actual or possible antiviral drugs and/or possible anti-sars-cov-2 activity including but not limited to remdesivir, chloroquine, hydroxychloroquine(unless used chronically for autoimmune diseases), dexamethasone, and other immunomodulatory agents and human immunodeficiency virusprotease inhibitorsfor therapeutic purpose of sars-cov-2 infection prior to study drug administration any sars-cov-2 human intravenous immunoglobulin, convalescent plasma for the treatment of sars-cov-2 infection prior to study drug administration any other investigational device or medical product including but not limited to any monoclonal antibody(tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of sars-cov-2 infection prior to the study drug administration. use of medications that are contraindicated with soc. sars-cov-2 vaccine prior to the study drug administration

patient with severe condition meeting one of the following: previously or currently hospitalized or requires hospitalization for treatment of serious sars-cov-2 related conditions. respiratory distress with respiratory rate ≥30 breaths/min. requires supplemental oxygen experience shock complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion. patient who has received or has a plan to receive any of following prohibited medications or treatments: drugs with actual or possible antiviral drugs and/or possible anti-sars-cov-2 activity including but not limited to remdesivir, chloroquine, hydroxychloroquine(unless used chronically for autoimmune diseases), dexamethasone, and other immunomodulatory agents and human immunodeficiency virusprotease inhibitorsfor therapeutic purpose of sars-cov-2 infection prior to study drug administration any sars-cov-2 human intravenous immunoglobulin, convalescent plasma for the treatment of sars-cov-2 infection prior to study drug administration any other investigational device or medical product including but not limited to any monoclonal antibody(tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of sars-cov-2 infection prior to the study drug administration. use of medications that are contraindicated with soc. sars-cov-2 vaccine prior to the study drug administration

patient with severe condition meeting one of the following: previous or currently hospitalized or requires hospitalization for treatment of serious sars-cov-2 related conditions. respiratory distress with respiratory rate ≥30 breaths/min. requires supplemental oxygen experience shock complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion. patient who has received or has a plan to receive any of following prohibited medications or treatments: drugs with actual or possible antiviral drugs and/or possible anti-sars-cov-2 activity including but not limited to remdesivir, chloroquine, hydroxychloroquine(unless used chronically for autoimmune diseases), dexamethasone,and other immunomodulatory agents and human immunodeficiency virusprotease inhibitorsfor therapeutic purpose of sars-cov-2 infection prior to study drug administration any sars-cov-2 human intravenousimmunoglobulin, convalescent plasma for the treatment of sars-cov-2 infection prior to study drug administration any other investigational device or medical product including but not limited to any monoclonal antibody(tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of sars-cov-2 infection prior to the study drug administration. use of medications that are contraindicated with soc. sars-cov-2 vaccine prior to the study drug administration

patient with severe condition meeting one of the following: previous or currently hospitalized or requires hospitalization for treatment of serious sars-cov-2 related conditions. respiratory distress with respiratory rate ≥30 breaths/min. requires supplemental oxygen experience shock complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion. patient who has received or has a plan to receive any of following prohibited medications or treatments: drugs with actual or possible antiviral drugs and/or possible anti-sars-cov-2 activity including but not limited to remdesivir, chloroquine, hydroxychloroquine(unless used chronically for autoimmune diseases), dexamethasone,and other immunomodulatory agents and human immunodeficiency virusprotease inhibitorsfor therapeutic purpose of sars-cov-2 infection prior to study drug administration any sars-cov-2 human intravenousimmunoglobulin, convalescent plasma for the treatment of sars-cov-2 infection prior to study drug administration any other investigational device or medical product including but not limited to any monoclonal antibody(tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of sars-cov-2 infection prior to the study drug administration. use of medications that are contraindicated with soc. sars-cov-2 vaccine prior to the study drug administration

1. patient with severe condition meeting one of the following: 1. previous or currently hospitalized or requires hospitalization for treatment of serious sars-cov-2 related conditions. 2. respiratory distress with respiratory rate ≥30 breaths/min. 3. requires supplemental oxygen 4. experience shock 5. complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion. 2. patient who has received or has a plan to receive any of following prohibited medications or treatments: 1. drugs with actual or possible antiviral drugs and/or possible anti-sars-cov-2 activity including but not limited to remdesivir, chloroquine, hydroxychloroquine(unless used chronically for autoimmune diseases), dexamethasone,and other immunomodulatory agents and human immunodeficiency virusprotease inhibitorsfor therapeutic purpose of sars-cov-2 infection prior to study drug administration 2. any sars-cov-2 human intravenousimmunoglobulin, convalescent plasma for the treatment of sars-cov-2 infection prior to study drug administration 3. any other investigational device or medical product including but not limited to any monoclonal antibody(tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of sars-cov-2 infection prior to the study drug administration. 4. use of medications that are contraindicated with soc. 5. sars-cov-2 vaccine prior to the study drug administration

1. patient with severe condition meeting one of the following: 1. previous or currently hospitalized or requires hospitalization for treatment of serious sars-cov-2 related conditions. 2. respiratory distress with respiratory rate ≥30 breaths/min. 3. requires supplemental oxygen 4. experience shock 5. complicated with other organs failure, and intensive care unit monitoring treatment is needed by investigator's discretion. 2. patient who has received or has a plan to receive any of following prohibited medications or treatments: 1. drugs with actual or possible antiviral drugs and/or possible anti-sars-cov-2 activity including but not limited to remdesivir, chloroquine, hydroxychloroquine(unless used chronically for autoimmune diseases), dexamethasone,and other immunomodulatory agents and human immunodeficiency virusprotease inhibitorsfor therapeutic purpose of sars-cov-2 infection prior to study drug administration 2. any sars-cov-2 human intravenousimmunoglobulin, convalescent plasma for the treatment of sars-cov-2 infection prior to study drug administration 3. any other investigational device or medical product including but not limited to any monoclonal antibody(tocilizumab, sarilumab, etc.), fusion proteins or biologics for the treatment of sars-cov-2 infection prior to the study drug administration. 4. use of medications that are contraindicated with soc. 5. sars-cov-2 vaccine prior to the study drug administration